Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan

(2012) Benjamin Chastek et al.   ADVANCES IN THERAPY

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population

(2012) Benjamin Chastek et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Psoriatic arthritis: update on pathophysiology, assessment and management

(2011) P. J. Mease   ANNALS OF THE RHEUMATIC DISEASES

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

(2011) D. E. Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2011) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

(2010) Léia CR Silva et al.   Immunotherapy

Comorbidities in Psoriasis Patients

(2010) Noori Kim et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

(2010) Sarah Thayer et al.   JOURNAL OF MEDICAL ECONOMICS

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

(2009) Amr A Saad et al.   ARTHRITIS RESEARCH & THERAPY